RS-tDCS for Cannabis Use Disorder: The C.A.R.E.S. Initiative

Part of paid clinical trials in New York, New York.

Sponsor
NYU Langone Health
Study ID
NCT07184983
Status
Recruiting
Apply to this trial

Conditions

  • Cannabis Use Disorder

Eligibility Criteria

Sex
ALL
Age
22 Years - 65 Years
Healthy Volunteers
Not accepted

Interventions

  • Active Transcranial Direct Current Stimulation (tDCS) — DEVICE
    tDCS is a noninvasive brain stimulation device that modulates brain activity by delivering low-intensity electrical current (2.0 mA) through scalp sponge electrodes. Device is programmed to ramp up to 2.0 mA (for 30 seconds), provide constant current throughout the session (19 minutes), and then ramp down (for 30 seconds) at the end.
  • Sham Transcranial Direct Current Stimulation (tDCS) — DEVICE
    tDCS is a noninvasive brain stimulation device that modulates brain activity by delivering low-intensity electrical current (2.0 mA) through scalp sponge electrodes. Device is programmed to ramp up to 2.0 mA (for 30 seconds) followed by a ramp down (30 seconds), with no current delivery for 18 minutes, and then ramp up (for 30 seconds) and down (for 30 seconds) at the end.
  • Mindfulness meditation — BEHAVIORAL
    Participants will follow an audio track for guided mindfulness during the stimulation.

Study Details

The purpose of this sham-controlled pilot randomized controlled trial (RCT) is to evaluate the feasibility, safety, and preliminary efficacy of a one-month intervention consisting of 20 home-based active or sham RS-tDCS sessions paired with audio track guided mindfulness meditation practice in otherwise healthy adults seeking to reduce cannabis use in the context of cannabis use disorder (CUD).

Key Dates

Start date
Nov 12, 2025
Status verified
Apr 2026
Primary completion
Oct 1, 2026
Completion
Oct 1, 2026

Study Design

Enrollment
46 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Active tDCS
    Participants will complete 20 remotely supervised (RS) daily sessions, each 20 minutes, of active dorsolateral prefrontal cortex (DLPFC) tDCS combined with mindfulness meditation.
  • Active Comparator: Sham tDCS
    Participants will complete 20 RS sham sessions, each 20 minutes, of active DLPFC tDCS combined with mindfulness meditation.

Primary Outcome Measure

The proportion of participants who complete at least 70% (14 out of 20) of intervention sessions [ Time Frame: End of treatment (up to 6 weeks) ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
NYU Langone HealthNew YorkNew York10016-

Find similar trials in New York, NY

By research site
NYU Langone Health· New York, NY

Related Studies